StockMarketWire.com - Oncology, inflammation and infectious diseases focused Tiziana Life Sciences said it had been granted a patent in the US related to its Milciclib treatment.
The issue from the United States Patent and Trademark Office was for use of Milciclib in combination with tyrosine kinase inhibitors, such as Sorafenib, Regorafenib and Lenvatinib, for the treatment of hepatocellular carcinoma and other cancers.
The patent would be published by the USPTO on 1 September as Patent No. 10,758,541.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.